Infection and Injection-Related Risks

Urgent guidance first

Spreading skin redness, warmth, pain, swelling or a red lump at an injection site, especially with fever, chills or sweating, can be a sign of infection such as cellulitis. [1] If the infection gets worse, it can lead to sepsis, a life-threatening emergency. MedlinePlus lists rapid breathing and heart rate, shortness of breath, confusion, extreme pain, and fever, shivering or clammy skin as symptoms, and says to get medical care right away. [2] In the United States, call 911 for severe symptoms (elsewhere, the local emergency number); for allergic-type symptoms such as swelling of the throat see allergic reactions.

This page describes risks. It gives no injection technique, preparation steps or storage-for-use instructions, and it offers no home checklist that could establish a product is safe, because none can.

Why injections are different

FDA explains that injectable products are delivered directly into the body, sometimes into the bloodstream, and so bypass some of the body's key defenses against toxins and microorganisms, which can lead to serious and life-threatening conditions. [3] In another warning letter, FDA said injectable drug products bypass many of the body's natural defenses and can lead to conditions such as septicemia or sepsis. [4]

Evidence labels used here: approved medicine, evidence of harm (for specific reported events), insufficient evidence and marketing claim.

Where infection risk can come from

Infection risk is not one thing. Several different problems can contribute, and they are separate from whether the peptide itself is active.

• The product. FDA says a compounded drug that does not meet quality standards, for example if it is contaminated, could cause serious injury or death. [5] Drugs that circumvent regulatory safeguards may be contaminated or counterfeit. [4]
• Fake or mislabeled sources. FDA has described fraudulent compounded semaglutide and tirzepatide with false label information, in some cases naming pharmacies that do not exist or that did not make the product. In one report tied to a product labeled as compounded tirzepatide, symptoms included redness, site swelling, pain and a red lump at the injection site. [6]
• Handling. FDA says reusing needles or syringes can result in contamination of a medication. [6] Equipment and handling details are the job of a clinician or pharmacist, not this page.
• The person. MedlinePlus lists risk factors for cellulitis that include breaks in the skin, diabetes, vascular disease and medicines that suppress the immune system. [1]

What the evidence says about unregulated supply

In a 2024 test-purchase study, researchers bought semaglutide vials from illegal online pharmacies. All three delivered vials were considered probable substandard or falsified. Samples had no viable microorganisms at the time of testing, but endotoxin was detected in all of them. [7] That study did not test research peptides, and it is one small purchase set, so it cannot be used to rank products. It does show that a no-growth microbiology result and an endotoxin result are different findings; see endotoxins, purity vs sterility.

Why there is no safe "home check"

Visible appearance, a certificate, or a vendor's claim cannot establish that an injectable is sterile and free of endotoxin. FDA recommends that appropriate components and finished products be tested for pyrogens and endotoxins, and it publishes manufacturing guidance for sterile drug products made by aseptic processing, which are industrial, regulated processes. [8][9] That is why this library offers no checklist.

People who should speak with a clinician first

People with diabetes, vascular disease, weakened immune systems, or a history of skin infections are listed among those at higher risk of cellulitis or sepsis. [1][2] Anyone considering any injectable product should discuss it with a licensed clinician, and see product quality and contamination.

Related guides

See peptide safety overview, cold-chain claims and counterfeit products and reporting adverse events.